B. Burtness Et Al. , "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study," LANCET , vol.394, no.10212, pp.1915-1928, 2019
Burtness, B. Et Al. 2019. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. LANCET , vol.394, no.10212 , 1915-1928.
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., de Castro, G., ... Psyrri, A.(2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. LANCET , vol.394, no.10212, 1915-1928.
Burtness, Barbara Et Al. "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study," LANCET , vol.394, no.10212, 1915-1928, 2019
Burtness, Barbara Et Al. "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study." LANCET , vol.394, no.10212, pp.1915-1928, 2019
Burtness, B. Et Al. (2019) . "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study." LANCET , vol.394, no.10212, pp.1915-1928.
@article{article, author={Barbara Burtness Et Al. }, title={Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study}, journal={LANCET}, year=2019, pages={1915-1928} }